Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Looking back over several decades, the path to pharmaceutical-grade polyethers took its time because chemists and manufacturers had to learn how to control molecules at a fine level. In the mid-1900s, industries first started pushing for more reliable, high-purity chemicals to support better medicines and processes. At this time, polyethers started catching attention because of their flexibility and stable performance in drug formulations. Over the years, health authorities in Europe and the United States developed standards like BP, EP, and USP monographs, pressing producers to remove impurities and nail down the right mix of properties. Researchers kept honing reaction conditions, often guided by real trial and error, sharing breakthroughs as new polymer chemistry came along. With better reactors and quality checks, polyether grades became more predictable, safe, and trustworthy for dosing in tablets, syrups, and injectable drugs. From garage-scale labs to high-tech production plants, the story shows how persistent work changed polyethers from rough industrial chemicals into vital pharmaceutical ingredients.
Polyether BP EP USP Pharma Grade stands out in today’s medicine world because it consistently holds up under strict testing for drug use. Factories churn out this polyether for use as a binder, base, or solubilizer, keeping in line with rules laid out in the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Unlike general-purpose grades, these products must prove their purity and chemical reliability through tough analysis. Each batch goes through hardness, color, clarity tests, and more, locking out harmful residues or variable performance that would put patients at risk. Drug makers rely on this dependable backbone for things like controlled drug release, taste masking, and stabilizing active compounds that break down easily in rough conditions. Polyethers for pharma need traceable batch records and clean processing lines, so final products carry clear guarantees—something that is non-negotiable once human health is involved.
Polyethers in pharma are long, chain-shaped molecules, usually clear or slightly cloudy liquids, sometimes available as waxy solids. Their molecular weights can range from a few hundred up to several thousand daltons, which directly impacts how they dissolve, mix, or interact with water and fats. For instance, as the polymer chains grow longer, their ability to blend with water shifts, often making them better at carrying oily drugs through the bloodstream. Their chemical backbone, typically built from repeating ether links, gives persistent stability even at the elevated temperatures used in making and packaging medicines. Many are nearly odorless and have a bland taste—two features that matter when mixing into syrups or chewable tablets. The low toxicity and barely-there taste make polyether a solid pick for medicine makers who want to protect, carry, or deliver drugs without making kids or sensitive patients gag at the flavor.
Regulatory bodies demand that each bottle or drum of polyether for pharma shows production lot, expiry, standardized molecular weight, and levels of possible contaminants like heavy metals or byproducts. In reality, labeling includes not just a fancy trade name, but raw data: pH, viscosity, melting point, and chemical structure info for anyone double-checking batch records. These specs match up with monographs from BP, EP, and USP. Agencies require this paper trail so drug firms can chase problems back to the source. Polyethers that fail even one part of this routine get pulled before anyone can use them—a risk no reputable supplier takes lightly. By sticking to these detailed rules, the industry lowers the chances of costly recalls or batch failures, making sure the stuff on the shelf is as safe as it is useful.
Polyethers for pharma typically grow from ring-opening polymerization, where small starter molecules link up, chain by chain, in carefully controlled reactors. Temperature, catalyst type, and monomer purity shape the final properties. Plants use sealed vessels and specialty glass or stainless fittings so reactive intermediates stay pure and don’t pick up solvents or metal ions along the way. After forming the main polyether backbone, workers wash, filter, and strip away leftover catalysts, then often pass the product through special columns to yank out anything the initial filters missed. Tightly regulated drying and packaging keep out water and dust. Every step, from monomer weighing to final drum-sealing, must stick to pharma-grade hygiene norms that make food lines look laid back by comparison. Keeping these ingredients pure takes both steady discipline and smart equipment choices—one wrong move, and the batch gets scrapped.
Once polyether leaves the reactor, scientists may tweak its properties for different drug applications. Attaching small side groups or linking different chain lengths creates a range of textures, melting points, and solubilities. For instance, some chemists attach polyethylene glycol (PEG) ends to boost water solubility, or swap out backbone atoms to make the polyether more flexible under cold or heat. Cross-linking, where two or more chains get “stitched” together, produces networks that hold water like a sponge—handy for slow-release tablets. These chemical edits stay under tight scrutiny, since every side group added must have a proven safety profile and predictable breakdown pattern in the body. Polyether’s versatility shows up in how easily chemists can add, remove, or switch parts to solve real-life drug delivery issues, from taste masking syrups to long-lasting implant coatings.
Pharma companies and scientists often refer to polyethers using a bunch of alternate names, including PEG, Polyethylene Oxide, or Macrogol (outside the US). Some brands use own trade names—like Carbowax or Pluriol—but at the base level, these refer to similar chains of repeating “ether” units. In BP and EP documents, names tie back to chemical structure, chain length, and test standards. Out in the market, the label could read simply “PEG 400,” “PEG 6000,” or “Macrogol 3350,” which points to the average molecular weight and gives drug developers quick check for matching the right grade to a medical need. Labeling consistency makes it easier for doctors, pharmacists, and regulators to stay on the same page, reducing actual mix-ups in the supply chain.
Manufacturers dealing in polyether pharma grade work under Good Manufacturing Practice (GMP) regulations. Floor workers suit up in gowns, gloves, and masks to prevent dust, hair, or germs from getting near the product stream. Plants set up routine clean-outs and in-line monitoring to catch odd smells or colors before anything gets into production batches. Regular training drills and strict signoffs make sure safety isn’t just talk—anyone caught skimping on protocol risks more than just a slap on the wrist. Since polyethers often land in injectables or childhood meds, companies face surprise audits, ingredient tracking, contamination checks, and tough recall systems, all rolled into their operating rhythm. Safety standards prevent slip-ups that would dump contaminants into the bloodstream, cementing trust between producer, hospital, and patient.
Polyether BP EP USP pharma grade shows up as a workhorse in almost every corner of the drug world. Drug designers blend it into tablets and capsules to help drugs release slowly, dissolve better, or withstand temperature extremes. In syrups and oral liquids, polyether keeps active ingredients suspended evenly and helps hide bitter or metallic flavors. For injectables, it carries hard-to-dissolve drugs into the bloodstream without causing reactions at the injection site. Surgeons and device makers rely on polyether's film-forming habits for wound dressings, irrigation solutions, and implant coatings, which cut down on tissue rejection and infection rates. Dermatologists pick topical gels with polyether to help skin medications penetrate without leaving sticky residue. From oral laxatives for children to cutting-edge cancer treatments, polyether pharma grade steps in quietly to make medicines work smoother, taste better, and act safer in the real world.
University labs and pharma R&D teams put polyether through its paces looking for new roles and better versions. Many studies target drug solubility problems, since thousands of new drugs fail in early tests just because they won’t dissolve or travel in the body. Polyether derivatives sometimes save a promising molecule from the scrap heap. Researchers build on decades of published work showing polyethers generally don’t provoke immune rejection or allergic reactions—the reason drug firms keep betting on this chemistry for new delivery systems like nanoparticles, micelles, or injectable depots. Tight collaboration between polymer chemists, medical doctors, and formulation scientists speeds up tweaks, troubleshooting, and scale-up moves, bringing better drugs to trials faster than before.
Toxicologists have run countless animal studies and long-term surveillance on polyether pharma grade, looking for delayed damage or build-up in the body. Findings published in journals and reviewed by regulatory agencies show low acute and chronic toxicity, even at quite high doses over long periods. Most polyethers pass harmlessly through urine or break down into safe byproducts. Sensitive organs—liver, kidney, lymph nodes—undergo careful checks during safety trials. For infants, cancer patients, or sensitive populations, researchers keep watching for rare reactions, but so far, risk ranks much lower than most other excipients. Routine screening also keeps tabs on potential contaminants like ethylene oxide or heavy metals that could slip into finished lots, covering gaps missed by older testing. The upshot—ongoing, transparent research gives confidence for expanding polyether use across more patient groups.
On the horizon, pharmaceutical polyethers face real challenges and big opportunities. With more precision drugs, custom therapies, and biologics coming onto the market, demand grows for polyethers that dissolve, carry, or stabilize exotic new actives. AI-driven drug design asks for quicker formulation swaps, which puts pressure on producers to deliver a library of polyether types, each tested for unique roles. Sustainability plays a bigger part every year, so clean production, lower-waste processes, and “greener” raw materials are getting more interest. Even as patents expire and knockoffs crowd in, trusted brands keep their edge by investing in better purification, tracking, and customer support—areas where cutting corners leaves a mark. With growing interest in personalized and pediatric medicine, next-generation polyethers could help drugs fit the needs of patients often left behind, widening access while raising safety and performance bars.
Polyether in its BP EP USP pharma grade form finds a steady spot in the world of medicine and health products. With roots in synthetic chemistry, it provides a backbone for many liquid and gel systems found in drug formulations. Think about cough syrups, oral suspensions, and topical creams—polyether helps stabilize these products, keeping their active ingredients consistently distributed. Over the years working with pharmacists and talking to people behind the scenes, the main things that stand out about polyether are reliability and chemical predictability. This quality turns it into a favorite among those tasked with developing both new treatments and everyday drugs.
It’s impossible to overstate the value of purity in pharmaceutical production. Polyether that meets BP, EP, and USP grades follows international standards. Those grade marks show that the substance jumps through the toughest purity hoops set by respected authorities like the British Pharmacopeia, European Pharmacopeia, and US Pharmacopeia. In practice, this means the polyether avoids risky contaminants that could easily slip into the mix and compromise the end product. That’s not just a technical detail—it’s about people's health and safety. The FDA reported in 2020 that about 12% of drug recalls came from contamination concerns. So for those working in pharma plants or regulatory labs, verified ingredients mark the difference between medicine that heals and medicine that harms.
This compound’s chemical flow suits both human and veterinary drugs. The most regular applications show up in oral syrups and gels, skin creams, and, less obviously, as part of capsule coatings or injectables. Polyether acts as a solubilizer, carrying drugs that resist dissolving in water so patients can take them by mouth. If you’ve ever struggled to get a child to swallow medicine, you’ve probably benefited from this surprising chemical. Drug makers prize polyether because it doesn’t react with actives or other excipients, giving maximum flexibility to their research and development teams. Polyoxyethylene glycol stands out during tablet production too, reducing powder clumping and letting machines run efficiently.
Sourcing for pharma isn’t just about price. Personally, I’ve heard plenty of stories where companies cut corners and ended up with off-grade chemicals. That can mean lost batches, delayed approvals, or worst-case scenarios like patient harm. Polyether of BP EP USP pharma grade basically reduces those risks down to a sliver. Its consistent viscosity and low toxicity get checked at every batch. Strong documentation trails show regulators that each barrel lives up to its reputation. The US Pharmacopeia notes that trust in quality ingredients reduces production stoppages and saves costs long-term—something any manufacturing manager will confirm.
Polyether opens up a path for better-designed drug delivery. In research, it helps bring forward slow-release treatments and smarter dosage forms. Scientists use it to fine-tune how drugs move through the body, so medicines hit the right spot at the right time. As new therapies for cancer, diabetes, and rare diseases develop, the need for reliable foundation materials like polyether grows. People worry about fake drugs in the global market—an issue flagged by the WHO, who estimates over 10% of medical products in some countries are substandard. The solution starts with established inputs and transparent supply chains. A basic ingredient with the right documentation can separate a life-saving medicine from a failed batch.
Pharmaceuticals hold lives in balance. Products like polyether BP EP USP pharma grade provide the foundation for safe manufacturing. Strong sourcing, clear testing, and honest labeling always stay more valuable than clever marketing or cheap substitutes. That’s a lesson worth remembering, both inside and outside the industry.
Anyone in pharmaceutical manufacturing learns pretty quickly that ingredient quality can make or break the final drug product. Polyether, used in a variety of drug formulations, often wears several hats—binder, stabilizer, sometimes even a solubilizer. Purity levels carry a real-world impact, affecting everything from patient safety to shelf-life. The pharma grade Polyether labeled BP, EP, or USP is specifically produced to meet well-defined requirements laid out by globally recognized pharmacopeias.
In pharma circles, it’s not enough to say “high purity.” The composition and presence—or absence—of certain substances need hard data behind them. Polyether BP EP USP Pharma Grade reflects this strictness. Key specifications usually include:
These numbers aren’t picked out of thin air. Each has roots in decades of toxicological data, real-world experience, and collaborative input from regulators and industry.
From experience, shortcutting on these purity specifications throws risk on the patient and erodes trust between manufacturers and healthcare providers. In hospitals, I’ve seen cases where contamination—even at low levels—leads to recalls or, worse, patient reactions. Endotoxin control marks another area that cannot be overlooked. Top-tier suppliers routinely include bacterial endotoxin testing (limulus amebocyte lysate LAL) with guaranteed results well below 0.5 EU/mg.
Manufacturers who don’t lock down their process, especially when blending, drying, or packing Polyether, end up facing batch rejections or regulatory scrutiny. The presence of even a small amount of residual organic solvents or cross-contaminants can mean starting over.
Many players invest heavily in in-house labs or partner with third-party testing outfits. High performance liquid chromatography, gas chromatography, and Karl Fischer titration run on every lot. Transparently sharing Certificates of Analysis keeps pharma buyers in the loop.
It’s pretty clear from regulatory documents and recalls that best practices stretch beyond testing. Suppliers who maintain ISO 9001 and GMP certification create more reliability. Some even take things further, applying additional purification—distillation, chromatography columns—to remove trace impurities, meeting even the strictest requirements for injectables and sensitive patients.
Drug makers—whether working with generics or specialty applications—watch these numbers closely. Consistency leads to predictability during tableting and capsule filling. Patients and pharmacies depend on drugs behaving the same way from one month to the next.
More players in the supply chain are demanding digital traceability. Smarter batch tracking and QR-coded Certificates of Analysis have started making waves in the industry. It allows quick response if an impurity does crop up. That extra accountability isn’t just for show; it lessens batch variability and boosts peace of mind on both sides of the prescription pad.
Ongoing refinement in Polyether purification and thorough third-party validation provide a better shot at safety. That matters whether someone’s making life-saving injectables or over-the-counter meds. The numbers printed on a spec sheet only matter if they’re real, validated, and understood as more than paperwork—they protect people.
Most folks don’t spend their days thinking about the small details behind the medicines in their cabinet, but those details shape safety and effectiveness in big ways. Polyether, used in pharma, often gets picked for its ability to dissolve and blend ingredients that the body needs to absorb. Its “BP EP USP” markings might look like code to anyone outside the labs, but they guarantee that this material passes the tight rules set by British, European, and US pharmacopeias. That kind of oversight isn’t just paperwork — it stops uncertainty before it sneaks into the pills people rely on.
In this industry, being “pharma grade” is no casual badge. Raw materials often reach labs from suppliers with different safety records. Pharmacists and scientists use substances that meet strict tests, including those for Polyether. The BP, EP, and USP standards mean the product cleared hurdles for purity, chemical content, and absence of harmful byproducts. Regulatory bodies require these proofs before allowing any substance inside a capsule, solution, or topical cream.
Polymers like polyethers, unless tightly controlled, can bring along trace pollutants, unreacted monomers, or heavy metals. In one published survey, substandard polyethers were linked to unpredictable drug release or, in rare cases, reactions inside the body. Reliable sources produce polyether batches that go through screenings with chromatography and spectroscopy, double-checking for even tiny unwanted chemicals. This might slow supply chains, but most patients feel safer if every ingredient inside their pills carries a certificate matching current regulations.
Quality mistakes cost more than a regulatory slap. In the early 2010s, a US drug company recalled medication due to a single excipient batch that slipped through lesser checks. Patients trust that what’s printed on the box matches what’s inside. One bad shipment can shatter that trust, especially with sensitive populations — think cancer patients or premature infants — who can’t afford risk.
Drug recalls always grab headlines, but many could have been stopped with routine testing. Pharma labs that insist on BP EP USP-grade polyether don’t just play it safe for compliance; they build a stronger case for patient health.
Some manufacturers argue steady audits add costs, but skimping brings bigger bills and reputational damage. Proper records for each drum or bag of polyether backtrack to its origin — not just for paperwork, but to track any problem if it ever pops up. Scientists also test for how polyether works under heat, light, or with other chemicals. Addressing these details can reveal interactions that common product tests don’t catch.
Quality control staff know boredom comes easier than breakthroughs when checking certificates and lab samples day after day. Even then, teams that overlook a single batch change can lose hard-earned progress. Investing in thorough routines, even during audits, cuts down on risk and keeps a closer connection to the patients at the other end of the supply chain.
Companies continuing to buy from certified suppliers, watching for updated standards, and supporting their in-house chemists build a safer industry for everyone. Publicly available reports from the FDA and European Medicines Agency offer insight into which excipient suppliers pass inspection. Investing in ongoing staff training, rather than only updating machinery, also helps catch emerging problems early.
A bottle of cough syrup or a tablet on a hospital tray passes through many hands before it arrives with the patient. Trust starts at the source. Reliable, tightly controlled pharma-grade polyether, checked against BP, EP, and USP standards every time, pulls that chain a little tighter.
Polyether BP EP USP Pharma Grade keeps showing up in places where high purity really counts. Any slip in storage or careless handling puts patients, products, and brands at risk. Those risks feel personal to anyone who's ever worked in a pharmacy or managed ingredients with a short shelf life. Every professional knows about the heartbreak of tossing out valuable product because a seal failed, condensation formed, or temperatures drifted. It's a painful waste of time and resources.
Companies store this grade of polyether in tightly sealed containers. Containers must shut out moisture. High humidity shortens shelf life. Even a little water creeping in encourages microbial growth, which might compromise batch integrity. Manufacturers usually pick stainless steel or high-grade plastic—anything that won’t react with the chemical or leach contaminants. Polyether won’t keep its quality on a dusty or sunlit shelf. Always choose a cool, dry warehouse space out of direct sunlight; ultraviolet light can speed up degradation.
Temperature swings threaten the delicate balance of a pharmaceutical ingredient. Polyether can lose purity or become unstable above 30°C. Cold won’t cause as many problems, but nobody recommends storing it much below room temperature either—especially if the warehouse runs into freezing weather.
A surprising number of contamination problems happen before the product ever reaches processing. It’s easy to shrug off the risk of cross-contact, especially if operations handle a range of chemicals. Separate storage zones often sound like overkill, but they stop cross-contamination dead in its tracks. I’ve watched batches recalled because someone opened a drum in the wrong space. Gloves, lab coats, and clean utensils—always non-reactive—help stop particles or residues from getting into the mix.
Staff training rarely gets enough attention. The most expensive safety measures mean little if warehouses rush, cut steps, or grow lax with hygiene protocols. Knowledge sticks best with real-world stories about what goes wrong: one careless move can waste an entire consignment.
Transport often leaves the ingredient exposed to short-term extremes. Trucks heat up fast in the sun, or chill down on the highway in winter. Logistics companies committed to pharmaceutical standards use temperature-tracked vehicles and audit reports. Polyether shouldn’t travel with volatile chemicals or strong-smelling substances; it absorbs odors, and nobody wants contamination flagged on arrival.
Every transfer—from manufacturer, to transport, to warehouse, to processing—needs records. Chain of custody forms, batch codes, and tamper-proof seals should all line up. Quality assurance teams should drill into this chain regularly; the industry has seen too many headlines about investigation failures that cost millions in recalls and lost customer trust.
Improvement starts with the basics: trained staff, strict temperature control, and unbreakable hygiene routines. Using automatic temperature and humidity logging systems makes life easier. Storing high-value pharma ingredients in access-controlled spaces avoids wandering drums and reduces incidents of mishandling. Audits, both third-party and internal, keep teams sharp and shine a light on potential weak spots before they turn into expensive mistakes.
In the end, safety and product quality depend closely on routine. Companies who treat routine as a living practice, not just a checklist, stay out of trouble. Suppliers and manufacturers who tackle every step with care give patients and pharmacists peace of mind, keeping those hard-earned reputations intact.
Standards like BP, EP, and USP shape the way we build trust in pharmaceutical materials. These acronyms stand for the British Pharmacopoeia, European Pharmacopoeia, and United States Pharmacopeia. They act as rulebooks for judging the quality, safety, and purity of substances that go into medicine, and those rules didn't come out of thin air. They’ve been shaped by decades of science, mistakes, and sometimes tragedy. If a supplier claims their polyether meets these benchmarks, it’s a serious claim, because patients’ lives sit on the other end.
Years working around pharmaceuticals taught me that cutting corners on excipients, even the ones that sound obscure, can grind the whole manufacturing process to a halt. Polyether, as a polymer, shows up in drug formulas, usually to help bind ingredients or stabilize them. There’s nothing glamorous about it, but if you buy a pharma-grade polyether and it secretly flunks the BP, EP, or USP standards, there’s no easy fix. Failed tests could mean things as simple as the presence of residual solvents, or as devastating as a toxic byproduct left behind in the polymerization process.
It’s tempting to fall for claims just because a product sports “pharma grade” on the bag. Real compliance means laboratory testing, consistent documentation, and open-book traceability. If you see a certificate of analysis that matches the most current BP/EP/USP monographs, you’re halfway there. There are stories in this industry of “certified” ingredients slipping through, only for defects to show up later. I've seen quality managers lose sleep and money over one non-compliant shipment because recalls are far uglier—and more expensive—than careful testing up front.
I used to think paperwork controlled everything. In reality, a piece of paper only gets you so far. Labs that supply materials for pharma clients routinely submit to audits. Inspectors come in, look at manufacturing practices, check purity testing data, and sometimes take their own samples right off the line. If suppliers stonewall when you ask about third-party audits or GMP certifications, that’s a red flag. Everyone wants the short list of “good” suppliers, but building one means checking backgrounds just as hard as you would for a new hire in your team.
Legally, pharma companies own the risk. Quality departments must double-check that every excipient and active ingredient is supported by actual compliance evidence, not just a line in a brochure. Regulators aren’t forgiving—“I thought it was compliant” won’t pass an FDA inspection. For polyether, just like any other ingredient meant for pharmaceutical use, companies need a full chain of documentation from raw material through final packaging.
It’s easy to say “follow the standards” but day-to-day business brings messy realities: changing suppliers, rushed deadlines, paperwork backlogs. One solution that’s worked is building a system of routine spot checks—random tests on received shipments, a double-check of certificates, an occasional blind sample sent to an outside lab. Real transparency comes from repeated proof, not a single checkbox ticked on a form. By investing energy up front in making sure polyether actually matches these high-bar standards, companies protect themselves, their partners, and, most importantly, the patients who depend on these medicines.
| Names | |
| Preferred IUPAC name | Poly(oxyethylene) |
| Other names |
Macrogol PEG Polyethylene glycol |
| Pronunciation | /ˌpɒliˈiːθər biː piː iː piː juː ɛs piː ˈfɑːrmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 25322-68-3 |
| Beilstein Reference | 3503779 |
| ChEBI | CHEBI:60004 |
| ChEMBL | CHEMBL1201560 |
| ChemSpider | 23712 |
| DrugBank | DB09531 |
| ECHA InfoCard | ECHA InfoCard: 02-2119752475-33-0000 |
| EC Number | 9003-11-6 |
| Gmelin Reference | Gmelin Reference: 17852 |
| KEGG | C11344 |
| MeSH | Polyethers"[MeSH] |
| PubChem CID | 5284350 |
| RTECS number | WL5276000 |
| UNII | HZD2X8J9F7 |
| UN number | UN1866 |
| CompTox Dashboard (EPA) | The CompTox Dashboard (EPA) identifier string for "Polyether BP EP USP Pharma Grade" is: **DTXSID10885250** |
| Properties | |
| Chemical formula | C2nH4n+2On+1 |
| Molar mass | 4000–5000 g/mol |
| Appearance | Clear, colorless, viscous liquid |
| Odor | Odorless |
| Density | 1.01 g/cm3 |
| Solubility in water | Soluble in water |
| Acidity (pKa) | ~14 |
| Basicity (pKb) | 7-9 (as 5% w/v solution) |
| Refractive index (nD) | 1.510 - 1.517 |
| Viscosity | 400-800 cP |
| Dipole moment | 1.7 D |
| Pharmacology | |
| ATC code | V09AX |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory irritation. |
| GHS labelling | GHS labelling: Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Precautionary statements: P261, P280, P305+P351+P338, P337+P313 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | >200°C |
| LD50 (median dose) | > 2380 mg/kg (Rat, oral) |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 2000 |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Polyethylene Glycol PEG 400 PEG 600 PEG 1500 PEG 3350 Macrogol Polysorbate 80 Propylene Glycol Polyoxyl 40 Stearate |
Chengguan District, Lanzhou, Gansu, China
